Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2023-11-21
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well enzalutamide with or without radium Ra 223
dichloride in treating patients with castration-resistant prostate cancer that has spread to
other places in the body. Enzalutamide is an androgen receptor inhibitor that may slow down
the growth of prostate cancer by blocking the action of the male hormone testosterone and
other male hormones called androgens. Radiation therapy uses high energy alpha particles to
kill tumor cells and shrink tumors. Enzalutamide with or without radium Ra 223 dichloride may
work better in treating patients with castration-resistant prostate cancer.